{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:13:46Z","timestamp":1790626426414,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AstraZeneca Rare Disease"},{"name":"Kyowa Kirin"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00198-023-06791-x","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T09:02:15Z","timestamp":1686301335000},"page":"1301-1310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Improving care pathways for people living with rare bone diseases (RBDs): outcomes from the first RBD Summit"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-8443","authenticated-orcid":false,"given":"Manju","family":"Chandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Petryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg Oliver","family":"Semler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Sleiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"6791_CR1","doi-asserted-by":"crossref","unstructured":"Unger S, Ferreira CR, Geert R, Mortier H et al (2023) Nosology of genetic skeletal disorders: 2023 revision. Am J Med Genet 1\u201346. https:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/ajmg.a.63132","DOI":"10.1002\/ajmg.a.63132"},{"key":"6791_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11914-020-00595-2","volume":"18","author":"LL Tosi","year":"2020","unstructured":"Tosi LL, Rajah EN, Stewart MH, Gillies AP, Hart TS, Lewiecki M (2020) The rare bone disease TeleECHO program: leveraging telehealth to improve rare bone disease. Care Curr Osteoporos Rep 18:344\u2013349. https:\/\/doi.org\/10.1007\/s11914-020-00595-2","journal-title":"Care Curr Osteoporos Rep"},{"key":"6791_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13023-019-1222-2","volume":"14","author":"AH Sabir","year":"2019","unstructured":"Sabir AH, Cole T (2019) The evolving therapeutic landscape of genetic skeletal disorders. Orphanet J Rare Dis 14:300. https:\/\/doi.org\/10.1186\/s13023-019-1222-2","journal-title":"Orphanet J Rare Dis"},{"key":"6791_CR4","unstructured":"The Economist Intelligence Unit. Leaving the darkness, seeing the light: a focus on people living with rare bone diseases. https:\/\/impact.economist.com\/perspectives\/sites\/default\/files\/eiu_rare_bone_diseases.pdf. Accessed 1 December 2022"},{"key":"6791_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s13023-020-01587-2","volume":"15","author":"D Dong","year":"2020","unstructured":"Dong D, Chung RY, Chan RH, Gong S, Xu RH (2020) Why is misdiagnosis more likely among some people with rare diseases than others? Insights from a population-based cross-sectional study in China. Orphanet J Rare Dis 15:307. https:\/\/doi.org\/10.1186\/s13023-020-01587-2","journal-title":"Orphanet J Rare Dis"},{"key":"6791_CR6","unstructured":"NORD Rare Insights. Barriers to rare disease diagnosis, care and treatment in the US: a 30-year comparative analysis. https:\/\/rarediseases.org\/wp-content\/uploads\/2020\/11\/NRD-2088-Barriers-30-Yr-Survey-Report_FNL-2.pdf. Accessed 9 January 2023"},{"key":"6791_CR7","doi-asserted-by":"publisher","first-page":"e654","DOI":"10.1542\/peds.2005-0469","volume":"116","author":"JA Kitterman","year":"2005","unstructured":"Kitterman JA, Kantanie S, Rocke DM, Kaplan FS (2005) Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics 116:e654\u2013e661. https:\/\/doi.org\/10.1542\/peds.2005-0469","journal-title":"Pediatrics"},{"key":"6791_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12969-019-0353-2","volume":"17","author":"A Skrabl-Baumgartner","year":"2019","unstructured":"Skrabl-Baumgartner A, Singer P, Greimel T, Gorkiewicz G, Hermann J (2019) Chronic non-bacterial osteomyelitis: a comparative study between children and adults. Pediatr Rheumatol Online J 17:49. https:\/\/doi.org\/10.1186\/s12969-019-0353-2","journal-title":"Pediatr Rheumatol Online J"},{"key":"6791_CR9","doi-asserted-by":"publisher","unstructured":"Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G et al (2016) The FAIR Guiding Principles for scientific data management and stewardship. Scientific data 3. https:\/\/doi.org\/10.1038\/sdata.2016.18","DOI":"10.1038\/sdata.2016.18"},{"key":"6791_CR10","unstructured":"European Registries for Rare Bone and Mineral Conditions (EuRR-Bone). https:\/\/eurr-bone.com. Accessed 9 January 2023"},{"key":"6791_CR11","unstructured":"Agency for Care Effectiveness (ACE), ACE Clinical Guidances (ACGs). Osteoporosis \u2013 identification and management in primary care. https:\/\/www.ace-hta.gov.sg\/healthcare-professionals\/ace-clinical-guidances-(acgs)\/details\/osteoporosis-identification-and-management-in-primary-care. Accessed 9 January 2023"},{"key":"6791_CR12","unstructured":"World Health Organization (WHO). Breast Cancer Awareness Month. https:\/\/www.who.int\/europe\/news-room\/events\/item\/2022\/10\/01\/default-calendar\/breast-cancer-awareness-month. Accessed 13 March 2023"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06791-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-023-06791-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06791-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T05:03:42Z","timestamp":1690520622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-023-06791-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["6791"],"URL":"https:\/\/doi.org\/10.1007\/s00198-023-06791-x","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]},"assertion":[{"value":"20 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"MC has received honoraria for speaking and chairing engagements from Kyowa Kirin. TOC receives clinical trial research support through his institution from Ultragenyx for studies related to XLH and Osteogenesis Imperfecta. He has received consulting fees and honoraria from Alexion, Inozyme (Medical Advisory Board), Ipsen, Kyowa Kirin (Advisory Board), Ultragenyx, and Viridian. TOC serves in an unpaid capacity on the Medical Advisory Board for the FD\/MAS Alliance, and the Scientific Advisory Boards of the XLH-Network, and Soft Bones (the US Hypophosphatasia Foundation). ECH receives clinical trial research support through his institution from Clementia Pharmaceuticals, an Ipsen Company, for studies related to FOP. He received prior clinical trials research support from Ultragenyx, Inc. for clinical trials research support through his institution for studies in osteogenesis imperfecta. ECH serves in an unpaid capacity on the Medical Advisory Board for the FD\/MAS Alliance, on the Medical Registry Advisory Board of the International FOP Association, and on the International Clinical Council for FOP. AP is employee of and may own stock\/options in Alexion, AstraZeneca Rare Disease. MS is an employee and shareholder of Ipsen. MD is a volunteer for the Rare Bone Disease Alliance Steering Committee. IA and JOS have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}